Mycology
Pneumocystis jirovecii (Pneumocystis pneumonia)
0 / 36 complete
0 / 3 complete
of complete
of complete
2022
2021
2020
2019
2018
2017
2016
dapsone p. 191
HIV-positive adults p. 174
immunocompromised patients p. 176
silver stain for p. 123
TMP-SMX p. 191
Pneumocystis jirovecii p. , 151
for Pneumocystis jirovecii p. , 151
Pneumocystis jirovecii p. , 151
Pneumocystis jirovecii p. , 151
Pneumocystis jirovecii p. , 151
Pneumocystis jirovecii p. , 151
for Pneumocystis jirovecii p. , 151
HIV-positive adults p. 174
prophylaxis p. 195
Pneumocystis jirovecii sometimes referred to as Pneumocystis carinii, is a fungus known to cause a severe lung infection called Pneumocystis pneumonia (PCP). PCP commonly affects individuals with weakened immune systems, such as people with HIV/AIDS, cancer patients receiving chemotherapy, or people taking immunosuppressive drugs. Symptoms of PCP can include fever, cough, shortness of breath, and difficulty breathing. Treatment typically involves antifungal medications, such as trimethoprim-sulfamethoxazole, pentamidine, or dapsone.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.